This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
SPARCL was a randomized, double-blind, parallel-design phase 4 treatment trial evaluating atorvastatin in patients with cardiovascular disease who had experienced a previous stroke.
| Feature | SPARCL |
|---|---|
| Condition | Cardiovascular Disease |
| Intervention | Atorvastatin (drug) |
| Design model | Parallel |
| Primary purpose | Treatment |
| Lead sponsor | Pfizer |
| Sponsor type | INDUSTRY |
| ClinicalTrials.gov identifier | NCT00147602 |
2. Clinical Question
The central clinical question was whether atorvastatin could affect the occurrence of stroke-related outcomes in patients with cardiovascular disease who had experienced a previous stroke.
Population
Patients with cardiovascular disease who have had a previous stroke.
Intervention
Atorvastatin treatment.
Comparator
The registry identifies a randomized comparison but does not provide additional comparator-arm details in the record reviewed here.
Primary question
Does atorvastatin influence time to occurrence of fatal or non-fatal stroke?
3. Trial Design
Enrollment
4732 patients
Randomization
Double masking
Parallel groups
Endpoint assessment
4. Primary Endpoint
| Endpoint | Definition |
|---|---|
| Time to occurrence of fatal or non-fatal stroke | Primary endpoint registered in ClinicalTrials.gov |
5. Planned Analysis
The registry identifies a time-to-event primary endpoint: time to occurrence of fatal or non-fatal stroke. For endpoints of this type, statistical analyses commonly use methods that account for follow-up time, censoring, and differences between randomized groups, such as Kaplan-Meier estimation, log-rank testing, and Cox proportional-hazards modeling.
Time-to-event methods are designed for studies where participants may have different lengths of follow-up and where not all participants experience the event before study completion.
6. Statistical Methods Explained
Why is a time-to-event endpoint used for stroke?
A time-to-event endpoint incorporates both whether a stroke occurred and when it occurred. This provides more information than simply comparing the proportion of participants who experienced a stroke by the end of follow-up.
Why does randomization matter?
Randomization helps balance known and unknown factors between treatment groups. This allows differences in outcomes to be interpreted as comparisons between assigned treatment strategies rather than simple differences between patient groups.
What does censoring mean?
Censoring occurs when a participant's exact event time is not observed during follow-up. Statistical survival methods use available follow-up information without assuming that censored participants experienced the event.
Why might a Cox model be used?
A Cox proportional-hazards model estimates the relative hazard between groups while accounting for the timing of events. The hazard ratio describes relative event rates over the analyzed follow-up period.
Why is double masking important?
Double masking can reduce the influence of expectations or knowledge of treatment assignment on participant behavior, outcome assessment, and reporting of events.
Why is enrollment size important?
A larger randomized population generally provides more information about event differences and improves the precision of estimated treatment effects.
7. Statistical Methodology
Kaplan-Meier estimation
Kaplan-Meier methods estimate the probability of remaining free from an event over time while accounting for censored observations.
Hazard ratios
If a hazard ratio is estimated, it summarizes the relative instantaneous event rate between groups. It does not directly represent the percentage of participants who experience the event or an absolute risk difference.
Confidence intervals
Confidence intervals describe uncertainty around an estimated treatment effect. Narrower intervals generally indicate greater statistical precision than wider intervals.
Intention-to-treat analysis
Randomized clinical trials commonly preserve treatment assignment during efficacy analyses so that comparisons reflect the strategy assigned at randomization.
8. Limitations
- Limited registry results: The ClinicalTrials.gov record reviewed here does not report statistical analyses or endpoint estimates.
- Endpoint interpretation: Time-to-event outcomes require consideration of follow-up duration, censoring, and the statistical model used.
- Missing methodological details: The registry information available here does not describe additional analysis specifications such as stratification, multiplicity procedures, or interim analyses.
- Generalizability: Interpretation applies to the enrolled population described in the registry: patients with cardiovascular disease who had experienced a previous stroke.
9. Why This Trial Matters Statistically
SPARCL is an important example of how randomized cardiovascular trials use time-to-event outcomes to evaluate prevention strategies. The design highlights several recurring statistical principles:
| Concept | How it appears in SPARCL |
|---|---|
| Randomization | Randomized allocation of treatment groups |
| Blinding | Double masking |
| Parallel design | Concurrent treatment-group comparison |
| Time-to-event analysis | Primary endpoint based on time to fatal or non-fatal stroke |
| Clinical endpoint definition | Stroke occurrence rather than a surrogate measurement |
10. Related Statistical Concepts
This trial connects to broader clinical-trial statistical methods used in cardiovascular research:
11. Sources
- ClinicalTrials.gov: NCT00147602.
- PubMed: SPARCL publication record.
- PubMed: Related publication record.
- PubMed: Related publication record.
- PubMed: Related publication record.
- PubMed: Related publication record.
Continue through Clinical Biostats
Explore additional clinical trial analyses, statistical tutorials, and calculators.
12. Record Summary
SPARCL demonstrates the structure of a randomized cardiovascular outcomes trial: a defined population, randomized allocation, double masking, parallel treatment groups, and a clinically meaningful time-to-event primary endpoint. The registry identifies the trial design and endpoint framework, while formal statistical results require the corresponding posted analyses and outcome reports.